Personalized Medince of Autoimmune Diseases

Future Perspectives for Personalized Medicine in Autoimmune Diseases

  • Antibody-Secreting Plasma Cells:
    • Depleting plasma cells while redirecting the immune response is a potential future direction.
    • Challenge: Understanding key processes and genes for plasma cell survival.
    • Ideal scenario: Targeting only pathogenic plasma cells to maintain protective immunity.

New Diagnostics and Preventive Medicine

  • New Diagnostics:
    • Challenge: Overlapping symptoms of autoimmune diseases.
    • Challenge: Lack of specific biomarkers for early diagnosis and monitoring.
    • Goal: Identify new biomarkers preceding clinical symptoms for early intervention.
    • Interrogate genomics, proteomics, and metabolomics to identify early disease signatures for individual patients.
    • This will help with disease stratification and personalized medicine.
  • Preventive Medicine:
    • Challenge: Understanding multiple environmental and genetic risk factors for autoimmunity.
    • Advances in genetics, immunology, and technologies are driving innovative prevention strategies.
    • Develop vaccines against pathogens linked to autoimmunity (e.g., Epstein-Barr virus).
    • Use AI and machine learning to analyze large datasets to predict disease outcome and optimize preventive strategies.
    • Develop individualized prevention plans based on genetic risk, environmental exposures, and lifestyle factors.

Summary of Personalized Medicine

  • Leverage genetic, molecular, and environmental data to tailor prevention, diagnosis, and treatment.
  • Focus on individual patient profiles to improve outcomes, reduce side effects, and optimize therapeutic efficacy.
  • Advances in technology, biomarker discovery, and targeted therapies can drive the future of personalized medicine in autoimmunity.

B Cell Targeting Biologics in SLE (as an Example)

  • Autoreactive B cells play an important role in the pathogenesis of autoimmunity.
  • Several B cell targeting biologics have been tested or are in clinical trials for autoimmune diseases.

B Cell Surface Targeting Monoclonal Antibodies

  • Rituximab:
    • Anti-CD20 monoclonal antibody (B cell depleting).
    • Depletes circulating B cells efficiently, but has variable efficacy in SLE.
    • Possibly due to incomplete depletion of CD20 negative long-lived plasma cells.
  • Botismib:
    • Induces plasma cell apoptosis.
    • Significant side effects (peripheral neuropathy and hematologic toxicities) prevent its use in treating SLE.
  • Atezazep:
    • Fusion protein that binds both BAFF and APRIL cytokines (critical for B cell survival and plasma cell differentiation).
    • Can reduce autoantibody production and infection.
    • Use in treating SLE is limited in the clinics due to strong effect in B cell depletion.
  • Daratumumab:
    • Anti-CD38 monoclonal antibody (targets plasma cells).
    • Depletes plasma cells directly through ADCC, CDC, and apoptosis.
    • Early clinical trials show promise in reducing disease activities.
    • Data is still limited and more research is needed.
  • Anti-CD19 CAR T Cells:
    • Engineered to target CD19 (surface protein on B cells and some plasma cells).
    • Recognize and kill CD19 positive cells, leading to deep and sustained B cell depletion.
    • CAR T cells can deplete tissue resident cells better than monoclonal antibodies.
    • Potential for long-term disease control with a single infusion.
    • High cost and complicated manufacturing process.
    • Risk of cytokine release syndrome and other immune-related toxicities.

Shift Towards Precision Medicine in SLE

  • These therapies represent a shift towards precision medicine in SLE, targeting specific components of the B cell pathway.
  • Ongoing research and clinical trials aim to optimize their use and expand treatment options for SLE patients.

Mechanisms of Action for B Cell Targeting Immunotherapies

  • B cell-mediated pathogenesis in autoimmune diseases involves autoantibody production, immune complex formation, antigen presentation, and cytokine secretion.
  • These mechanisms drive inflammation, tissue damage, and organ dysfunction.
  • Targeting B cells is a key therapeutic strategy for many autoimmune diseases.

Rituximab

  • Monoclonal antibody targeting CD20 (B cell surface marker) to deplete B cells.
  • Approved for therapeutic use and a cornerstone in the treatment of various conditions.
  • Updated versions of rituximab exist (some are fully humanized).
  • Mechanisms of Action:
    • Antibody-dependent cellular cytotoxicity (ADCC): Immune cells (e.g., NK cells) recognize and kill rituximab-bound B cells.
    • Complement-dependent cytotoxicity (CDC): Activates the complement system to lyse B cells.
    • Direct apoptosis: Binding of rituximab to B cells induces direct apoptosis.

BAF (B Cell Activating Factor)

  • BAFF, also known as BLyS (B Lymphocyte Stimulator), is a cytokine critical for B cell survival, maturation, and activation.
  • Essential for maintaining B cell homeostasis.
  • Binds to three receptors: BAFF-R, TACI, and BCMA.
  • Promotes the survival of immature and mature B cells by preventing apoptosis.
  • Supports the differentiation of B cells into antibody-secreting cells.
Role in Autoimmunity
  • Overproduction of BAFF leads to the survival of autoreactive B cells, contributing to autoantibody production and autoimmune diseases.
Belimumab
  • Anti-BAFF monoclonal antibody.
  • Neutralizes circulating BAFF to block its binding to receptors and downstream signaling pathways.
  • Approved for SLE, but has only moderate efficacy.
  • Better biologics are still under investigation.

Targeting Intracellular Kinase Pathways (JAK-STAT)

  • The JAK-STAT pathway is a critical intracellular signaling mechanism that transmits information from extracellular cytokines, growth factors, and hormones to the cell nucleus.
  • Regulates key cellular processes: immune responses, cell growth, differentiation, and apoptosis.

Mechanism of JAK-STAT Signaling

  1. Ligand Binding: Cytokine (e.g., IL-6) binds to its receptor, causing receptor dimerization.
  2. JAK Activation: Receptor-associated JAKs are brought into proximity and phosphorylate each other.
  3. Receptor Phosphorylation: JAKs phosphorylate specific tyrosine residues on the receptor, creating docking sites for STAT proteins.
  4. STAT Activation: STAT proteins bind to the phosphorylated receptor and are then phosphorylated by JAKs.
  5. STAT Dimerization and Translocation: Phosphorylated STATs dimerize and translocate to the nucleus.
  6. Gene Regulation: STAT dimer binds to specific DNA sequences to regulate expression of target genes involved in downstream pathways.

JAK-STAT Inhibitors

  • Small molecule inhibitors that competitively inhibit at the JAK kinase phosphorylation sites.
  • Examples: Baricitinib, Tofacitinib; approved for treating rheumatoid arthritis and other autoimmune diseases.

Treatment for Autoimmune Diseases

  • Conventional Treatments: Corticosteroids suppress general immune function to modulate uncontrolled inflammation.
    • Limitations: Heterogeneous patient population and significant side effects (increased risk of infection due to non-selective immune suppression).
  • Current Treatments: Aim to more selectively inhibit inflammatory signals while minimizing disruption to homeostatic immune functions.
  • Targeted Immunotherapy: Widespread use due to advances in understanding disease pathogenesis and new drug manufacturing techniques.
    • Main Targets:
      • Pro-inflammatory cytokines.
      • Signaling pathways leading to the transcription of inflammatory mediators (mediated by intracellular kinases).
      • Effector cells (autoreactive B cells and autoantibody-secreting plasma cells).

Cytokine Targeting Therapies

TNF-alpha

  • A potent pro-inflammatory cytokine with a central role in immune regulation, inflammation, and apoptosis.
  • Produced primarily by activated macrophages, but also by T cells, NK cells, and other immune cells.
  • Physiological Functions: Activates immune cells and enhances antigen presentation; regulates cell growth and differentiation.
  • Pathological Functions: Promotes inflammation by inducing the expression of adhesion molecules, chemokines, and other pro-inflammatory cytokines (e.g., IL-6).
    • In rheumatoid arthritis: Drives synovial inflammation, cartilage destruction, and bone erosion.
    • In SLE: Contributes to systemic inflammation and organ damage.
  • Treatment Strategy: Anti-TNF-alpha monoclonal antibodies and fusion proteins to neutralize circulating TNF-alpha.
  • Examples: Adalimumab (used for rheumatoid arthritis and juvenile idiopathic arthritis).

IL-6

  • Signaling transduced through a complex of the IL-6 receptor and glycoprotein 130 (GP130).
  • Dimerization of GP130 activates multiple signaling pathways (STAT, MAPK, and PI3K), increasing the transcription of pro-inflammatory mediators.
  • Physiological Functions: Stimulates B cell differentiation into plasma cells; promotes T cell differentiation into Th17 cells; supports growth and differentiation of hematopoietic stem cells; plays a role in wound healing and tissue regeneration.
  • Pathological Functions: Promotes inflammation by inducing the production of acute-phase proteins and other pro-inflammatory cytokines.
  • Treatment Strategy: Anti-IL-6 receptor monoclonal antibodies (block binding of circulating IL-6 to its receptor).
  • Example: Tocilizumab (approved for rheumatoid arthritis and juvenile idiopathic arthritis, especially in those not responding to anti-TNF-alpha treatment).

Type I Interferon

  • A paper in 2016 identified a strong interferon signature in SLE patient blood samples.
  • Type I interferons (primarily interferon-alpha and beta) play a crucial role in the innate immune response to viral infection.
  • Produced by various cells, including plasmacytoid dendritic cells, macrophages, and fibroblasts.
  • Physiological Functions: Enhance antigen presentation; activate NK cells and cytotoxic T cells; regulate cell proliferation, differentiation, and apoptosis.
  • Pathological Functions: Promote inflammation and are central to SLE pathogenesis, driving autoantibody production and systemic inflammation.
  • Treatment Strategy: Anifrolumab: Blocks interferon-alpha receptor.
  • Approval and Efficacy: Approved for SLE treatment, but efficacy is moderate; still among the few approved biologics for SLE.